Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study - Concepedia

Concepedia

Publication | Open Access

Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study

DOI Full Paper Access

35

Citations

17

References

2022

Year

Luigi Gargiulo, Luciano Ibba, Giulia Pavia, Carlo Alberto Vignoli, Francesco Piscazzi, Mario Valenti, Federica Sanna, Chiara Perugini, Jessica Avagliano, Antonio Costanzo,

Dermatology and Therapy

Abstract

Our findings confirmed that risankizumab is a safe and effective therapeutic option for the treatment of a wide "real-life" cohort of patients with psoriasis.

References

	Year	Citations

Page 1